title: Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records.
abstract: It is unclear which maintenance treatment for bipolar disorder is superior in clinical practice. Randomized controlled head-to-head trials of available drugs either do not exist or are inconclusive. We aimed to compare rates of monotherapy treatment failure in individuals prescribed lithium, valproate, olanzapine or quetiapine by a population-based cohort study using electronic health records. 5,089 patients with bipolar disorder were prescribed lithium (N=1,505), valproate (N=1,173) olanzapine (N=1,366) or quetiapine (N=1,075) as monotherapy. Treatment failure was defined as time to stopping medication or add-on of another mood stabilizer, antipsychotic, antidepressant or benzodiazepine. In unadjusted analyses, the duration of successful monotherapy was longest in individuals treated with lithium. Treatment failure had occurred in 75% of those prescribed lithium by 2.05 years (95% CI: 1.63-2.51), compared to 0.76 years (95% CI: 0.64-0.84) for those prescribed quetiapine, 0.98 years (95% CI: 0.84-1.18) for those prescribed valproate, and 1.13 years for those prescribed olanzapine (95% CI: 1.00-1.31). Lithium's superiority remained in a propensity score matched analysis; when treatment failure was defined as stopping medication or add-on of a mood stabilizer or antipsychotic; and when treatment failure was restricted to more than three months after commencing the study drug. Lithium appears to be more successful as monotherapy maintenance treatment than valproate, olanzapine or quetiapine. Lithium is often avoided because of its side effect profile, but alternative treatments may reduce the time to being prescribed more than one drug, with potential additive side effects of these treatments.
authors.affiliation: Division of Psychiatry, University College London, London, W1T 7NF, UK.
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Hayes
authors.affiliation: Department of Primary Care and Population Health, University College London, London, UK.
authors.forename: Louise
authors.initials: L
authors.lastname: Marston
authors.affiliation: Department of Primary Care and Population Health, University College London, London, UK.
authors.forename: Kate
authors.initials: K
authors.lastname: Walters
authors.affiliation: Department of Psychiatry, University of Oxford, Oxford, UK.
authors.forename: John R
authors.initials: JR
authors.lastname: Geddes
authors.affiliation: Division of Psychiatry, University College London, London, W1T 7NF, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: King
authors.affiliation: Division of Psychiatry, University College London, London, W1T 7NF, UK.
authors.forename: David P J
authors.initials: DP
authors.lastname: Osborn
keywords: Bipolar disorder; cohort study; electronic health records; lithium; maintenance treatment; olanzapine; quetiapine; valproate
references.citation: Stat Med. 1998 Oct 15;17(19):2265-81
references.pmid: 9802183
references.citation: Bipolar Disord. 2013 Feb;15(1):1-44
references.pmid: 23237061
references.citation: Am J Psychiatry. 2001 Oct;158(10 ):1719-22
references.pmid: 11579009
references.citation: Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):76-83
references.pmid: 19065600
references.citation: Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):64-9
references.pmid: 23124958
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):715-21
references.pmid: 19345251
references.citation: Am J Epidemiol. 1999 Aug 15;150(4):327-33
references.pmid: 10453808
references.citation: Inform Prim Care. 2011;19(4):251-5
references.pmid: 22828580
references.citation: J Clin Epidemiol. 1995 Mar;48(3):431-43
references.pmid: 7897464
references.citation: Stat Med. 2005 May 30;24(10):1563-78
references.pmid: 15706581
references.citation: Psychiatr Serv. 2007 Jun;58(6):855-63
references.pmid: 17535948
references.citation: Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):704-7
references.pmid: 19455565
references.citation: Lancet. 1992 Oct 17;340(8825):944-6
references.pmid: 1357352
references.citation: BMJ. 1996 May 11;312(7040):1215-8
references.pmid: 8634569
references.citation: PLoS One. 2011;6(12 ):e28725
references.pmid: 22163329
references.citation: CNS Drugs. 2002;16(11):721-9
references.pmid: 12383028
references.citation: BMJ. 1993 Jul 3;307(6895):32-4
references.pmid: 8343670
references.citation: Am J Psychiatry. 2006 Feb;163(2):217-24
references.pmid: 16449474
references.citation: Lancet. 2010 Jan 30;375(9712):385-95
references.pmid: 20092882
references.citation: PLoS One. 2013 Dec 12;8(12 ):e82365
references.pmid: 24349267
references.citation: Singapore Med J. 2011 Dec;52(12):914-8; quiz 919
references.pmid: 22159936
references.citation: Am J Psychiatry. 2004 Jan;161(1):3-18
references.pmid: 14702242
references.citation: Lancet. 1997 May 17;349(9063):1436-42
references.pmid: 9164317
references.citation: Bipolar Disord. 2006 Jun;8(3):232-41
references.pmid: 16696824
references.citation: Lancet Psychiatry. 2014 Oct;1(5):351-9
references.pmid: 26360999
references.citation: Lancet. 2015 Aug 1;386(9992):461-8
references.pmid: 26003379
references.citation: BMJ. 1990 Apr 28;300(6732):1092
references.pmid: 2344534
references.citation: Arch Gen Psychiatry. 2000 May;57(5):490-2
references.pmid: 10807489
references.citation: Int J Bipolar Disord. 2014 Dec 20;2:15
references.pmid: 25530932